Equities analysts forecast that Bruker Co. (NASDAQ:BRKR) will post $455.80 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Bruker’s earnings, with estimates ranging from $449.90 million to $465.00 million. Bruker posted sales of $435.60 million in the same quarter last year, which would indicate a positive year over year growth rate of 4.6%. The business is scheduled to issue its next earnings results on Thursday, November 1st.

According to Zacks, analysts expect that Bruker will report full-year sales of $1.88 billion for the current year, with estimates ranging from $1.85 billion to $1.90 billion. For the next year, analysts forecast that the company will report sales of $1.94 billion per share, with estimates ranging from $1.92 billion to $1.96 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Bruker.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, August 2nd. The medical research company reported $0.25 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.25. The company had revenue of $443.70 million during the quarter, compared to the consensus estimate of $436.10 million. Bruker had a return on equity of 27.03% and a net margin of 4.99%. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.23 earnings per share.

Several research analysts have recently weighed in on BRKR shares. BidaskClub cut Bruker from a “buy” rating to a “hold” rating in a research report on Friday, April 27th. Bank of America reduced their price objective on Bruker from $37.00 to $34.00 and set a “neutral” rating for the company in a research report on Friday, May 4th. BTIG Research set a $42.00 price objective on Bruker and gave the stock a “buy” rating in a research report on Sunday, May 6th. Zacks Investment Research raised Bruker from a “hold” rating to a “buy” rating and set a $34.00 price objective for the company in a research report on Tuesday, May 8th. Finally, ValuEngine cut Bruker from a “hold” rating to a “sell” rating in a research report on Wednesday, July 11th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $33.20.

Hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in Bruker during the second quarter valued at approximately $101,000. Meeder Asset Management Inc. boosted its position in Bruker by 501.4% during the first quarter. Meeder Asset Management Inc. now owns 4,697 shares of the medical research company’s stock valued at $140,000 after purchasing an additional 3,916 shares during the last quarter. Sun Life Financial INC acquired a new position in Bruker during the second quarter valued at approximately $163,000. TLP Group LLC acquired a new position in Bruker during the first quarter valued at approximately $190,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Bruker during the first quarter valued at approximately $242,000. 63.59% of the stock is owned by hedge funds and other institutional investors.

BRKR stock opened at $34.36 on Tuesday. The company has a quick ratio of 1.27, a current ratio of 2.22 and a debt-to-equity ratio of 0.26. The stock has a market cap of $5.30 billion, a PE ratio of 28.40, a PEG ratio of 2.14 and a beta of 1.17. Bruker has a fifty-two week low of $27.58 and a fifty-two week high of $36.53.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 21st. Stockholders of record on Tuesday, September 4th will be given a dividend of $0.04 per share. The ex-dividend date is Friday, August 31st. This represents a $0.16 annualized dividend and a dividend yield of 0.47%. Bruker’s dividend payout ratio is currently 13.22%.

Bruker Company Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

See Also: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Bruker (BRKR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.